News for RaQualia Pharma Inc. (4579.T)

Published at

Jun 9, 2023 8:28 AM

by marketscreener.com

positive

positive

ASKA Pharmaceutical : June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma

Press Release ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with... | June 9, 2023

4579.T

Read more →
Published at

Mar 14, 2022 5:15 PM

by prnewswire.com

mixed

mixed

Global CIPN Industry Review 2017-2021 and Forecast 2022-2030 - CIPN Medications Account for More Than 55% Share of Therapies in 2021

/PRNewswire/ -- The "Global Chemotherapy-Induced Peripheral Neuropathy Market, By Therapy, By Region, Estimation & Forecast, 2017 - 2030" report has been added...

ROGN.MX ROG.SW RO.SW RHHVF RHHBY RHHBF PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE HTSUF BDSI 4579.T 4530.T 0TDF.L 0QQ6.L 003850.KS ABTCL.SN ABT.SN ABT

Read more →
Published at

Mar 9, 2022 3:18 AM

by seekingalpha.com

mixed

mixed

Artelo Biosciences (ARTL): Rounding A Corner With Cannabinoid-Based Therapy

Artelo Biosciences has made good progress with a therapy that could bring relief to cancer suffers. Read more to know why ARTL could be possible market leader.

ZEG.DE AZNN.MX AZNCF AZN.L AZN 0A4J.L FGEN.MX FGEN 0IL8.L IPSEY IPNN.MX IPN.PA 4579.T

Read more →
Published at

Dec 20, 2021 7:10 AM

by marketscreener.com

positive

positive

Hisamitsu Pharmaceutical : RaQualia Pharma and Hisamitsu Pharmaceutical have agreed to enter into a license agreement for a novel sodium channel blocker

PRESS RELEASE RaQualia Pharma Inc. Hisamitsu Pharmaceutical Co., Inc. December 20, 2021 RaQualia... | December 20, 2021

HTSUF 4579.T 4530.T

Read more →

News for RaQualia Pharma Inc. (4579.T)

ASKA Pharmaceutical : June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma

Global CIPN Industry Review 2017-2021 and Forecast 2022-2030 - CIPN Medications Account for More Than 55% Share of Therapies in 2021

Artelo Biosciences (ARTL): Rounding A Corner With Cannabinoid-Based Therapy

Hisamitsu Pharmaceutical : RaQualia Pharma and Hisamitsu Pharmaceutical have agreed to enter into a license agreement for a novel sodium channel blocker